Reference
Medicines and Healthcare products Regulatory Agency. Insulins (all types): risk of cutaneous amyloidosis at injection site. Drug Safety Update 14: 10-12, No. 2, Sep 2020. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/920770/Sept-2020-DSU-PDF.pdf
Rights and permissions
About this article
Cite this article
Cutaneous amyloidosis at insulin injection site. Reactions Weekly 1825, 1 (2020). https://doi.org/10.1007/s40278-020-84241-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-84241-1